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“Vision for the Future” 
- The Challenge
It is estimated that over 9 million people over the age of 40 have early 
signs of Age-related Macular Degeneration - the most common cause 
of decreased vision in people over 65. 
For almost 90% of these patients no effective treatment is available. 
Diabetic retinopathy also affects millions of individuals and the numbers 
are rising rapidly due to an increase in the incidence of juvenile and type 
2 diabetes. 
Glaucoma, another thief of sight among otherwise healthy adults, is the 
most common cause of decreased vision in the African-American 
population. Effective treatment options for both are not available.
“Vision for the Future” 
- The Challenge
In the US over 9 million people 
over the age of 40 have  
Age-related Macular 
Degeneration or AMD.
No effective treatment is available 
for 90% of patients. 
“Vision for the Future” 
- The Challenge
Diabetic retinopathy
affects over 4 million individuals. 
The numbers are rising rapidly 
due to an increase in the 
incidence of juvenile and type 2 
diabetes. 
Effective long-term treatment 
options are not available.
“Vision for the Future” 
- The Challenge
Glaucoma affects over 4 
million people in the US –
most common cause of vision 
loss in African-Americans. 
Effective long-term treatment 
options are not available.
“Vision for the Future” 
- The Answer
With the formation of the new Vision Research Center 
Kansas City is well on its way to becoming a 
national center for eye research where 
these ocular diseases and others are being researched 
to develop new therapy approaches urgently needed by 
physicians in the US and worldwide, 
transferring basic science findings seamlessly into 
practical use with patients.
“Vision for the Future” 
- The Answer
Objectives of the Vision Research Center:
 direct avenue for basic and translational 
research
 educational excellence 
 ensure patients receive the most advanced 
medical treatments available
“Vision for the Future” 
- The Answer
The Vision Research Center:
Collaboration between UMKC and Kansas City 
Medical Centers offers an unprecedented 
interdisciplinary synergy with a unified goal: 
to better diagnose, prevent, and treat eye 
disease and vision disorders in order to make a 
difference in the lives of tens of millions of 
people worldwide.
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Translational Research
Pharmaceuticals
Biologicals
Nutrition
Biologicals / Sensor Technology
Micro- / Nano-Sensor Technology
Devices
Facilities
Clinical Research
Clinical Research
Ongoing Clinical Trials
Age-Related Macular Degeneration 
 Neovista - A phase II randomized study involving the use of an intravitreal pharmaceutical agent, alone or with Epirad90 treatment. 
For potential treatment of subfoveal choroidal neovascularization associated with wet macular degeneration.
 Regeneron AMD - A phase III study involving the use of an intravitreal pharmaceutical agent that is already FDA approved called 
Lucentis versus an investigational pharmaceutical agent.  For the potential treatment of subfoveal choroidal neovascularization
associated with wet macular degeneration.
 Macusight AMD - A phase II study involving the combined use of an FDA approved pharmaceutical agent called Lucentis with an 
investigational pharmaceutical agent. For the potential treatment of subfoveal choroidal neovascularization associated with wet 
macular degeneration.
 Age-Related Eye Disease Study (AREDS) - The Eye Foundation was selected by the National Eye Institute as a study site for 
AREDS II, a multi-center randomized trial of 4,000 participants. This Phase III study is attempted to determine whether high 
supplemental doses of lutein, zeaxanthin and omega-3 fatty acides affect the development of advanced AMD. (closed)
 Sirion Trial - A phase II study involving the use of an investigational systemic medication to potentially treat dry macular degeneration. 
(closed)
 Alimera Diabetic Trials - Two phase II trials involving investigational intravitreal inserts of a slow release medication to potentially 
inhibit the growth of abnormal blood vessels associated with diabetic retinopathy. (closed)
 Rise Trial - A phase III trial involving the intravitreal injection of an investigational medication to potentially inhibit the growth of 
abnormal blood vessels associated with diabetic retinopathy. (closed)
 Allergan Trial - A phase II study involving an intravitreal drug delivery system, sometimes in combination with laser. This trial is for 
potentially inhibiting the growth of abnormal blood vessels associated with diabetic retinopathy. (closed)
Clinical Research
Ongoing Clinical Trials
Diabetic Retinopathy
 Regeneron DME - A phase II study involving the use of an investigational intravitreal pharmaceutical 
agent to potentially inhibit the growth of abnormal blood vessels associated with diabetic eye disease.
 Macusight DME - A phase II study involving the use of an investigational intravitreal pharmaceutical 
agent to potentially inhibit the growth of abnormal blood vessels associated with diabetic eye disease.
 Alimera Diabetic Trials - Two phase II trials involving investigational intravitreal inserts of a slow release 
medication to potentially inhibit the growth of abnormal blood vessels associated with diabetic retinopathy. 
(closed)
 Rise Trial - A phase III trial involving the intravitreal injection of an investigational medication to 
potentially inhibit the growth of abnormal blood vessels associated with diabetic retinopathy. (closed)
 Allergan Trial - A phase II study involving an intravitreal drug delivery system, sometimes in combination 
with laser. This trial is for potentially inhibiting the growth of abnormal blood vessels associated with 
diabetic retinopathy. (closed)
Clinical Research
Ongoing Clinical Trials
Vitreomacular Traction 
(Macular Pucker/Macular Hole)
 Thrombogenics - A phase III study involving the use of an 
investigational intravitreal pharmaceutical agent to potentially release 
vitreal traction of macula and potentially close small macular holes.  
These conditions have traditionally been treated surgically.
Visual Rehabilitation Therapy Trial
 Novavision VRT - A potential vision restoration therapy using 
complex stimuli in patients with central vision loss due to dry 
maculopathy.
Patient Care
“Vision for the Future” 
- The Answer
The Vision Research Center continues to gain 
national prominence through publications in various 
professional journals and presentations at scientific 
conferences by its faculty members, researchers, 
post-doctoral associates, and graduate students. It 
also provides significant opportunities for students 
and doctors in training at UMKC to work on 
innovative research studies.
